AEterna Zentaris (STU:ET80) Scaled Net Operating Assets : -0.44 (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AEterna Zentaris's operating assets for the quarter that ended in Mar. 2024 was €2.07 Mil. AEterna Zentaris's operating liabilities for the quarter that ended in Mar. 2024 was €17.10 Mil. AEterna Zentaris's Total Assets for the quarter that ended in Dec. 2023 was €33.94 Mil. Therefore, AEterna Zentaris's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.44.

AEterna Zentaris Scaled Net Operating Assets Historical Data

The historical data trend for AEterna Zentaris's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Scaled Net Operating Assets Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.39

-0.50

-0.35

-0.20

-0.27

AEterna Zentaris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.27	-0.25	-0.27	-0.36	-0.44

Competitive Comparison of AEterna Zentaris's Scaled Net Operating Assets

For the Biotechnology subindustry, AEterna Zentaris's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Scaled Net Operating Assets falls into.

AEterna Zentaris Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

AEterna Zentaris's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(2.751	-	17.002)	/	52.889
=	-0.27

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	33.944	-	31.193
=	2.751

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	17.258	-	0.109	-	0.147
=	17.002

AEterna Zentaris's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(2.068	-	17.1)	/	33.944
=	-0.44

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	29.249	-	27.181
=	2.068

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	17.316	-	0.074	-	0.142
=	17.1

AEterna Zentaris Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (STU:ET80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

AEZS:USA AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines